Literature DB >> 35039902

Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.

Carissa A Hansen1, Douglas R Miller2, Stephanie Annarumma3, Carley T Rusch3,4, Adolfo Ramirez-Zamora4, Habibeh Khoshbouei5.   

Abstract

Over the past two decades, animal models of Parkinson's disease (PD) have helped to determine the plausible underlying mechanism of levo-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia following L-DOPA treatment. However, our understanding of the mechanisms related to this phenomenon remains incomplete. The purpose of this manuscript is to provide a comprehensive review of treatment protocols used for assessing the occurrence of L-DOPA-induced dyskinesia, L-DOPA absorption, distribution, drug/food interaction, and discuss current strategies and future directions. This review offers a historical perspective using L-DOPA in animal models of PD and the occurrence of L-DOPA-induced dyskinesia.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Diet; Dopamine; L-DOPA; Parkinson’s disease

Mesh：

Substances：

Year:  2022        PMID： 35039902      PMCID： PMC9124678          DOI： 10.1007/s00415-022-10963-w

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   6.682


  81 in total

1.  An essay on the shaking palsy. 1817.

Authors:  James Parkinson
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

2.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

3.  'Rejuvenation' protects neurons in mouse models of Parkinson's disease.

Authors:  C Savio Chan; Jaime N Guzman; Ema Ilijic; Jeff N Mercer; Caroline Rick; Tatiana Tkatch; Gloria E Meredith; D James Surmeier
Journal:  Nature       Date:  2007-06-10       Impact factor: 49.962

4.  A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia.

Authors:  R A Hauser; J Friedlander; T A Zesiewicz; C H Adler; L C Seeberger; C F O'Brien; E S Molho; S A Factor
Journal:  Clin Neuropharmacol       Date:  2000 Mar-Apr       Impact factor: 1.592

Review 5.  Parkinson disease.

Authors:  Werner Poewe; Klaus Seppi; Caroline M Tanner; Glenda M Halliday; Patrik Brundin; Jens Volkmann; Anette-Eleonore Schrag; Anthony E Lang
Journal:  Nat Rev Dis Primers       Date:  2017-03-23       Impact factor: 52.329

6.  Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.

Authors:  Mariese A Hely; John G L Morris; Wayne G J Reid; Robert Trafficante
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

Review 7.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

8.  A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

Authors:  M Lundblad; B Picconi; H Lindgren; M A Cenci
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

Review 9.  Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Authors:  Elmyra V Encarnacion; Robert A Hauser
Journal:  Eur Neurol       Date:  2008-05-15       Impact factor: 1.710

Review 10.  Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.

Authors:  Alice Manson; Paola Stirpe; Anette Schrag
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.